Biocon · NSE: BIOCON · BSE: 532523
Q1 FY25 results · Apr–Jun 2024
Biocon reported revenue from operations of ₹3,432.90 crore (up 0.3% from Q1 FY24) and net profit of ₹861.80 crore (up 478.8% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,432.90 | 3,422.60 | +0.3% | 3,917.10 | −12.4% |
| Other income | 1,134.50 | 93.50 | 12x | 48.60 | 23x |
| Total income | 4,567.40 | 3,516.10 | +29.9% | 3,965.70 | +15.2% |
| Profit before tax | 1,145.50 | 216.90 | +428.1% | 321.70 | +256.1% |
| Net profit for the period | 861.80 | 148.90 | +478.8% | 222.90 | +286.6% |
| Attributable to shareholders of the company | 659.70 | 101.40 | +550.6% | 135.50 | +386.9% |
| EPS, basic (₹) | 5.51 | 0.85 | +548.2% | 1.13 | +387.6% |
| Net margin (%) | 25.1 | 4.4 | 5.7 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 510.60 | 513.20 | −0.5% | 532.60 | −4.1% |
| Other income | 41.90 | 36.00 | +16.4% | 38.90 | +7.7% |
| Total income | 552.50 | 549.20 | +0.6% | 571.50 | −3.3% |
| Profit before tax | 1.10 | 49.60 | −97.8% | 21.80 | −95.0% |
| Net profit for the period | 0.90 | 46.60 | −98.1% | 14.00 | −93.6% |
| EPS, basic (₹) | 0.01 | 0.39 | −97.4% | 0.12 | −91.7% |
| Net margin (%) | 0.2 | 9.1 | 2.6 |
Consolidated
- Filed with BSE
- 09 Aug 2024, 12:41 IST
- Board meeting
- 08 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Aug 2024, 12:41 IST
- Board meeting
- 08 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE